Description:

Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension; ODM derived from: https://clinicaltrials.gov/show/NCT00403650

Link:

https://clinicaltrials.gov/show/NCT00403650

Keywords:
Versions (1) ▾
  1. 6/20/17
Uploaded on:

June 20, 2017

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Sarcoidosis NCT00403650

Details

Eligibility Sarcoidosis NCT00403650

  1. StudyEvent: Eligibility
    1. Eligibility Sarcoidosis NCT00403650
Inclusion Criteria
patients with known sarcoidosis 17
age 18 or greater
patients with documented pulmonary hypertension with a pa mean > 25 mm as measured by cardiac catheterization within six months of entry into the study
patients with dyspnea
six minute walk distance of between 100 to 500 meters
patients on stable immunotherapy for their sarcoidosis, including prednisone, methotrexate, azathioprine, hydroxychloroquine, cyclophosphamide, thalidomide, and/or infliximab
patients able to provide written consent
Exclusion Criteria
patients on pulmonary vasodilator drugs (flolan, remodulin, bosentan, sildenafil) in the prior 28 days (patients on stable dose of calcium channel blocker for more than 1 month prior to right heart catheterization can be continued on the calcium channel blocker)
patients with severe airway obstruction as defined by fev1/fvc of less than 35%
patients with world health organization (who) class iv status
patients who are pregnant or breast feeding
patients with significant left ventricular dysfunction with a left ventricular ejection fraction of less than 35%
significant liver dysfunction not due to sarcoidosis
patients with severe other organ disease felt by investigators to impact survival during the course of the study
patients unable to perform the 6 inhalation treatments required for therapy
patients with < 90 mm hg systolic systemic blood pressure will be excluded
Back to the top of the page